Past, Present, and Future of Chronic Kidney Disease Anemia Management in the United States

Advances in Chronic Kidney Disease

Volumn 16, Issue 2, 2009, Pages 101-108

  Wish, Jay B ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Anemia; Economics; ESAs; Hemoglobin level; Reimbursement

Indexed keywords

ANTIANEMIC AGENT; ANTIBIOTIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRIC HYDROXIDE SUCROSE; FERRIC PYROPHOSPHATE; FERRITIN; FERROUS GLUCONATE; FERUMOXYTOL; HEMOGLOBIN; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; VITAMIN D DERIVATIVE;

ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON STORAGE; IRON THERAPY; MEDICARE; PRIORITY JOURNAL; REIMBURSEMENT; RISK MANAGEMENT; UNITED STATES;

ANEMIA, IRON-DEFICIENCY; DRUG COSTS; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 60149108837     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2008.12.005     Document Type: Article

References (27)

1. Eggers P.W., Greer J., and Jencks S. The use of Health Care Financing Administration data for the development of a quality improvement project on the treatment of anemia. Am J Kidney Dis 24 (1994) 247-254
2. National Kidney Foundation. DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 37 Suppl 3 (1997) S192-S240
3. Health Care Financing Administration. 1998 Annual Report, End Stage Renal Disease Core Indicators Project (1998), Department of Health and Human Services, Health Standards Quality Bureau, Baltimore MD
4. Centers for Medicare & Medicaid Services: 2007 Annual Report, End Stage Renal Disease Clinical Performance Measures Project (December 2007), Department of Health and Human Services, Centers for Medicare and Medicaid Services, Office of Clinical Standards & Quality, Baltimore, MD
5. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47 Suppl 3 (2006) S1-S145
6. Centers for Medicare and Medicaid Services: 2005 Annual Report, End Stage Renal Disease Clinical Performance Measures Project (2005), Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards & Quality, Baltimore, MD
7. Singh A., Sczcech L., Teng K.L., et al. Correction of anemia with epoetin alpha in chronic kidney disease. N Engl J Med 355 (2006) 2085-2096
8. Drüeke T., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
9. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
10. National Kidney Foundation. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50 (2007) 471-530
11. Besarab A., Reyes C.M., and Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 40 (2002) 439-446
12. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 37 Suppl 1 (2001) S182-S238
13. Pisoni R.L. Erythropoietin therapy in Europe: Results from the DOPPS. Contrib Nephrol 137 (2002) 396-402
14. Canadian Society of Nephrology. Clinical practice guidelines for the management of anemia associated with chronic kidney disease. Kidney Int 74 Suppl 110 (2008) S1-S24
15. Wish J.B. Can evidence drive the development of a sound national EPO reimbursement policy?. Am J Kidney Dis 41 (2003) 254-258
16. Lacson Jr. E., Ofsthun N., and Lazarus J.M. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 41 (2003) 111-124
17. Besarab A., Kaiser J.W., and Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 34 (1999) 173-176
18. Besarab A., Amin N., Ahsan M., et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11 (2000) 530-538
19. Kalantar-Zadeh K., Lee G.H., Miller J.E., et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis (2009) (in press)
20. Kapoian T., O'Mara N.B., Singh A.K., et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19 (2008) 372-379
21. Pizzi L.T., Benz T.J., Goldfarb D.S., et al. Ferric gluconate yields cost-savings in hemodialysis patients with high ferritin and low TSAT: Results from the DRIVE studies. J Am Soc Nephrol 18 (2007) 207A abstr
22. Spinowitz B.S., Kausz A.T., Baptista J., et al. Ferumoxytol for treating iron deficiency in CKD. J Am Soc Nephrol 19 (2008) 1599-1605
23. Gupta A., Amin N.B., Besarab A., et al. Dialysate iron therapy: Infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int 55 (1999) 1891-1898
24. United States Renal Data System: USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases (2007), National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
25. Wish J.B. The economic realities of erythropoiesis-stimulating agent therapy in kidney disease. Kidney Int 70 Suppl 104 (2006) S21-S25
26. Del Vecchio L., and Locatelli F. New erythropoiesis-stimulating agents: how innovative are they?. Contrib Nephrol 161 (2008) 255-260
27. Bradbury B.D., Wang O., Critchlow C.W., et al. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 51 (2008) 62-70